---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-23-000898"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T05:06:30.977274+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CVS Health launches Cordavis subsidiary; first biosimilar Hyrimoz at >80% lower list price than Humira

## Summary
- Launched Cordavis, a wholly owned subsidiary to commercialize and co-produce biosimilar products in the U.S.
- First product: Cordavis private-label Hyrimoz (adalimumab-adaz) from Sandoz, launching Q1 2024.
- List price of Cordavis Hyrimoz will be more than 80% lower than current Humira list price.
- U.S. biosimilar market projected to grow from <$10B in 2022 to >$100B by 2029.
- CVS CFO states Cordavis will help ensure sufficient biosimilar supply and reduce drug costs for consumers.

## SEC filing metadata
- accession: 0000947871-23-000898
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/0000947871-23-000898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/ss2413675_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-23-000898
- JSON: https://secwatch.observer/filing/0000947871-23-000898.json
- Plain text: https://secwatch.observer/filing/0000947871-23-000898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.